AbbVie targets 2015 growth with focus on new specialty drugs Chicago Daily Herald AbbVie also is developing daclizumab, a treatment for multiple sclerosis in the late stage of clinical trials that may reach the market by late 2015 or early 2016. Finally, the company has elagolix, a drug for endometriosis. The uterine disease affects ... |
